CYT Cyteir Therapeutics, Inc.Stock Price & Overview
$2.800.00 (0.00%)4:00 PM 09/22/23
NASDAQ | $USD | Post-Market: $2.76 -0.04 (-1.43%) 4:34 PM
Charts
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close
Quant Ranking
Ratings Summary
| Now | 6M ago | |
|---|---|---|
SA Analysts | Not CoveredRating: Not Covered | |
Wall Street | Not CoveredRating: Not Covered | |
Quant | Not CoveredRating: Not Covered | |
Ratings Summary
SA Analysts
Wall Street
Quant
| Now | 3M ago | 6M ago | |
|---|---|---|---|
Valuation | -Rating: Not Covered | ||
Growth | -Rating: Not Covered | ||
Profitability | -Rating: Not Covered | ||
Momentum | -Rating: Not Covered | ||
Revisions | -Rating: Not Covered | ||
See CYT ratings with Premium.
Company Profile
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
Address
- 128 Spring Street
- Building A
- Suite 510
- Lexington, MA, 02421
- United States
Phone Number
857 285 4140
Website